Vedolizumab to prevent postoperative recurrence of Crohn&apos;s disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial

Inflammatory Bowel Disease

Effect of mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease on postoperative endoscopic recurrence (SPICY): an international, randomised controlled trial

Lancet Gastroenterol Hepatol

van der Does de Willebois EML, Bellato V, Duijvestein M, van der Bilt JDW, van Dongen K, Spinelli A, D'Haens GR, Mundt MW, Furfaro F, Danese S, Vignali A, Bemelman WA, Buskens CJ, SPICY collaborator group

doi: 10.1016/S2468-1253(24)00097-9

Gastrointestinal Cancer

Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial

Lancet Gastroenterol Hepatol

Chia JWK, Segelov E, Deng Y, Ho GF, Wang W, Han S, Sharma A, Ding K, Chen G, Jeffery MG, Tham CK, Ahn JB, Nott L, Zielinski R, Chao TY, van Hagen T, Wei PL, Day F, Mehta S, Yau T, Peng J, Hayes TM, Li Y, Gandhi M, Foo EMJ, Rahman N, Rothwell P, Ali R, Simes J, Toh HC

doi: 10.1016/S2468-1253(24)00387-X

Inflammatory Bowel Disease

Mucosal Healing With Vedolizumab in Patients with Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled Trial

Clin Gastroenterol Hepatol

Jairath V, Feagan BG, Silverberg MS, Danese S, Gionchetti P, Löwenberg M, Bressler B, Ferrante M, Hart A, Lindner D, Escher A, Jones S, Shen B, Travis S

doi: 10.1016/j.cgh.2024.06.037

Inflammatory Bowel Disease

Efficacy of Ustekinumab and Vedolizumab Among Postoperative Crohn's Disease Patients as Postoperative Prophylaxis and Rescue Therapy: Real-world Data

Inflamm Bowel Dis

Ertem FU, Rivers CR, Ghaffari AA, Watson AR, Tang G, Schwartz M, Johnston E, Barrie A, Harrison J, Dueker JM, Hartman D, Binion DG

doi: 10.1093/ibd/izae137

Inflammatory Bowel Disease

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY)

J Crohns Colitis

Colombel JF, Sandborn WJ, Schreiber S, Danese S, Kłopocka M, Kierkuś J, Kulynych R, Gonciarz M, Sołtysiak A, Smoliński P, Srećković S, Valuyskikh E, Lahat A, Horyński M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Kim JM, Park G, Lee J, Lee J, Ryu JY, Sands BE, Hanauer SB

doi: 10.1093/ecco-jcc/jjaf060

Inflammatory Bowel Disease

Placebo rates in Crohn's disease randomized clinical trials: An individual patient data meta-analysis

Gastroenterology

Solitano V, Hogan M, Singh S, Danese S, Peyrin-Biroulet L, Zou G, Yuan Y, Sands BE, Feagan BG, Dulai PS, Narula N, Ma C, Jairath V

doi: 10.1053/j.gastro.2024.10.009

ColonoscopyInflammatory Bowel Disease

Diagnostic Accuracy of Non-Invasive Biomarkers and Imaging for Evaluating Postoperative Recurrence in Crohn's Disease

Clin Gastroenterol Hepatol

Samnani S, Ray CM, Gill P, Stein L, Buhler KA, Leong RW, Smith RL, De Cruz P, Kaplan GG, Seow CH, Lu C, Guizzetti L, Hoentjen F, Marshall JK, Singh S, Panaccione R, Novak KL, Ma C

doi: 10.1016/j.cgh.2025.03.030

Inflammatory Bowel Disease

Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU

Gut

Gisbert JP, Donday MG, Riestra S, Lucendo AJ, Benítez JM, Navarro-Llavat M, Barrio J, Morales-Alvarado VJ, Rivero M, Busquets D, Leo Carnerero E, Merino O, Nantes Castillejo Ó, Navarro P, Van Domselaar M, Gutiérrez A, Alonso-Abreu I, Mejuto R, Fernández-Salazar L, Iborra M, Martín-Arranz MD, Pineda JR, Sampedro MJ, Serra Nilsson K, Bouhmidi A, Batista L, Muñoz Villafranca C, Rodríguez-Lago I, Ceballos D, Guerra I, Mañosa M, Marín Jiménez I, Torrella E, Vera Mendoza M, Casanova MJ, de Francisco R, Arias-González L, Marín Pedrosa S, García-Bosch O, García-Alonso FJ, Delgado-Guillena P, García MJ, Torrealba L, Núñez-Ortiz A, Vicuña Arregui M, Bosca-Watts MM, Blázquez I, Acosta D, Garre A, Baldán M, Martínez C, Barreiro-de Acosta M, Domènech E, Esteve M, García-Sánchez V, Nos P, Panés J, Chaparro M, EXIT Study group of GETECCU

doi: 10.1136/gutjnl-2024-333385

Inflammatory Bowel Disease

IL-23p19 Antagonists vs. Ustekinumab for Treatment of Crohn's Disease: A Meta-analysis of Randomized Controlled Trials

Am J Gastroenterol

Dziegielewski C, Yuan Y, Ma C, Boland BS, Chang JT, Syal G, Vuyyuru SK, Peyrin-Biroulet L, Jairath V, Singh S

doi: 10.14309/ajg.0000000000003406

Related content

Effect of mesenteric sparing or extended resection in primary ileocolic resection for Crohn's disease on postoperative endoscopic recurrence (SPICY): an international, randomised controlled trial

Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): an international, multicentre, phase 3, randomised, double-blind, placebo-controlled trial

Mucosal Healing With Vedolizumab in Patients with Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled Trial

Efficacy of Ustekinumab and Vedolizumab Among Postoperative Crohn's Disease Patients as Postoperative Prophylaxis and Rescue Therapy: Real-world Data

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY)

Placebo rates in Crohn's disease randomized clinical trials: An individual patient data meta-analysis

Diagnostic Accuracy of Non-Invasive Biomarkers and Imaging for Evaluating Postoperative Recurrence in Crohn's Disease

Withdrawal of antitumour necrosis factor in inflammatory bowel disease patients in remission: a randomised placebo-controlled clinical trial of GETECCU

IL-23p19 Antagonists vs. Ustekinumab for Treatment of Crohn's Disease: A Meta-analysis of Randomized Controlled Trials